Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)

Summary

The study objective is to see if IV Efgartigimod and Vyjuvek treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) and IV Efgartigimod treatment in Epidermolysis Bullosa Acquisita (EBA) improves wound healing and affects the levels of C7 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 antibodies could improve quality of life.

Timeline

Start

2026-07

Primary completion

2028-01

Completion

2028-01

Drugs

Indications